Today's Daily Dose brings you news about Bristol-Myers' CheckMate -743 study results; Cyclacel Pharma's entry into COVID-19 drug bandwagon; Exelixis touching a new 52-week high and Novartis exploring anti-malaria drug for COVID-19.

Let's take a look at the biotech/pharma companies that are slated to report clinical trial results this quarter.

Probi's largest clinical trial ever, focused on probiotic immune health, has recently been completed.

Over the years, attendees of MAGI Clinical Research Conferences have collected a set of practical, actionable suggestions for improving clinical trials. More than eighty such tips appear in the July 2019 edition of Journal of Clinical Research Best Practices*.  In this post, Polaris auditors weigh in on some of their favorite MAGI suggestions. Surprising no one, they also were eager to share some of their own.

Our Favorites Tips from MAGI

So how does a clinical trial tip earn a spot on our exalted Faves List?  First, it must be something we don’t see too often, or not as much as we’d like.(If most organizations already do a useful thing, it doesn’t really qualify as a helpful tip; it’s really just a common practice.) Second, the effort to implement the tip can’t be too onerous. If a practice requires too much interdepartmental coordination, change management, training, money, or resources, it’s not a tip. It’s a full-blown initiative.

So here they are. Each tip from MAGI attendees is in bold font. Our accompanying commentary is in plain text:

• To help ensure quality study conduct, clinical sites should prepare protocol-specific quality checklists for each study. We’ve written about quality checklists from the auditing perspective before. They’re not a panacea, certainly, but that doesn’t mean they can’t be very useful.
  
  
• After study close-out, sponsors and CROs should consider holding conference calls with groups of sites to capture lessons learned. This in turn could be used to improve training, SOPs, SIVs, etc.
  
  
• As a recruitment aid, clinical sites should create pocket-sized, laminated study cards that list the inclusion/exclusion criteria for a study.  Site staff members can keep these cards in their lab coat pockets and quickly refer to them when treating a patient who could be a potential subject.
  
  
• CROs should share risk assessments and mitigation plans with Sponsors. We agree, but would also encourage CROs to keep the sites involved and aware of risks so they can anticipate them and proceed accordingly.
  
  
• Sponsors/CROs should ensure proper qualifications of vendors prior to executing contracts. It’s hard to argue with this logic, but we don’t see it as much as we should. Too often qualification audits come after the paperwork has been signed. Should the audit uncover noncompliance or quality risks at the vendor site, it’s much harder to get the vendor to make necessary changes after the contract is in place.
  
  
• CROs should align 3rd party contracts with the Sponsor/CRO contract and the Clinical Trial Agreement. Yep.

Additional Tips from Polaris QA/Compliance Auditors

The MAGI list of clinical trial tips brought others to mind that we wanted to share. We applied the same criteria to these suggestions as we did to the MAGI contributions: (1) not necessarily rare, but not as common as it could be, and (2) not overly complex or expensive to implement.

• When evaluating outsourcing partners and clinical sites, Sponsors and CROs should make sure to look at personnel turnover rates. Frequent turnovers may suggest underlying problems that could jeopardize study conduct and quality.
  
  
• Sponsors and CROs should make sure their Monitoring Report templates are consistent with the Clinical Monitoring Plan (CMP). For example:
  
  
• The CMP calls for a focus on a particular set of critical variables, but the report template only has a place for recording that 100% SDV was completed. This means that there’s no way to document that the monitor put special emphasis on anything.
• The CMP requires bi-direction review of study data – a confirmation that what is in the CRF can be verified in the source, and all pertinent data in the source can be found in the CRF – but the report template only allows for the former to be documented.
  
  
• Every member of the site team has valuable input. It’s important to include the study PI, CRC, pharmacist, and other key personnel in the discussions. In 2017, we wrote an article about the important, yet often overlooked, input that the pharmacist on site can provide.
  
  
• There are many reasons that trial participants leave a study, many of which can’t be remedied with improved site practices. But sites that demonstrate they value the participation of their study volunteers, and honor the time they’re spending and contribution they’re making, tend to have better retention results. To that end:
  
  
• To help participants schedule their time, sites can prepare calendars that include all study visit dates and indicate the activities and procedures they entail. (This, of course, needs to be approved by the IRB).
• When participants arrive, they shouldn’t have to sit in a waiting room or empty exam room; they should be seen immediately so they don’t feel their time is being wasted.
• Sites can provide beverages and light snacks to their study participants who especially appreciate them immediately after a fasting blood draw (protocol permitting, naturally). It’s a small courtesy, and not difficult to do. Whose day isn’t brightened by a proffered nosh?**

Uh oh. Now we got you all thinking about mini muffins and cheddar popcorn. Go ahead. Grab a treat. We'll talk later.

________________________________________________________________
 * Journal of Clinical Research Best Practices, July 2019

** Proffered Nosh™ would be a really great name for a restaurant. Or a fictional Scotland Yard Inspector -- legendary for his wit, brilliance, wine pairings, and fashion sense.

The results of a 33-patient study conducted by a Burlington biotech suggest its long-acting steroid injection for osteoarthritis of the knee may be safer for the large percentage of those patients who also have type 2 diabetes. Flexion Therapeutics (Nasdaq: FLXN) has for years been developing its lead drug candidate, Zilretta (formerly called FX006), a reformulation of a common corticosteroid that’s used with osteoarthritis patients. Flexion’s version combines the drug with a employs proprietary…

• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

- Libtayo decreased the risk of death by 32.4% compared to chemotherapy

Much attention has been paid to the impact of the COVID-19 pandemic on the supply chain for medicines we rely on, but there has been less focus on the impact of medicines yet to come. The advancements in cancer care … Continue reading →

Newron will terminate work on its experimental Rett syndrome drug sarizotan after a complete failure in its pivotal STARS trial.

Alnylam and Vir Biotechnology have identified an anti-SARS-CoV-2 development candidate, putting them on track to start testing the inhaled RNAi treatment for COVID-19 in humans around the end of the year.

Moderna is finalizing the protocol for a phase 3 trial of its COVID-19 vaccine with a view to starting the study early in the summer. The establishment of the timeline, which follows FDA clearance to run a phase 2 trial, puts Moderna on track to win approval for its mRNA vaccine mRNA-1273 next year.

Experts caution that even promising early results don’t guarantee that vaccines will be widely available anytime soon.

The Global Mega Trial by WHO named Solidarity will include the study and testing of 4 promising drugs in order to develop an antidote of Coronavirus.

Charles Ebinger writes about India's ongoing efforts to achieve climate targets while balancing other considerations.

Adele Morris, Pietro Nivola and Charles Schultze scrutinize the rationale and efficacy of increased clean-energy expenditures from the U.S. government since 2008. The authors review the history of energy technology policy, examine the policy's environmental and energy- independence rationales, discuss political challenges and reasons for backing clean energy and offer their own policy recommendations.

Since 1995, Africa’s explosive economic growth has taken place without the changes in economic structure that normally occur as incomes per person rise. In particular, Africa’s experience with industrialization has been disappointing, especially as, historically, industry has been a driving force behind structural change. The East Asian “Miracle” is a manufacturing success story, but sub-Saharan…

Although African countries enjoyed fast economic growth based on high commodity prices over the past decade, this growth has not translated into the economic transformation the continent needs to eradicate extreme poverty and enjoy economic prosperity. Now, more than ever, the necessity for Africa to industrialize is being stressed at various international forums, ranging from…

Sunday, November 20 marked another United Nations “Africa Industrialization Day.” If anything, the level of attention to industrializing Africa coming from regional organizations, the multilateral development banks, and national governments has increased since the last one. This year, the new president of the African Development Bank flagged industrial development as one of his “high five”…

The nation is seeing accelerating gaps in economic opportunity and prosperity between more educated, tech-savvy, knowledge workers congregating in the nation’s “superstar” cities (and a few university-town hothouses) and residents of older industrial cities and the small towns of “flyover country.” These growing divides are shaping public discourse, as policymakers and thought leaders advance recipes…

In Paris this past December, 195 nations came to an historical agreement to reduce carbon emissions and limit the devastating impacts of climate change. While it was indeed a triumphant event worthy of great praise, these nations are now faced with the daunting task of having to achieve their intended climate goals. For many developing…

An old warehouse is transformed into a three-level open office with lots of shared spaces for a tech company in Vancouver.

A state of emergency has been declared in Hungary where four people are dead, 120 injured and six missing as torrents of red toxic sludge, the byproduct of bauxite refining for aluminum, burst from a containment pond and poured through six villages in

Great news for TreeHuggers in South America: Uruguay could become the first country in the region to authorize the cultivation of industrial hemp, according to El Pais newspaper. The national Ministry of Cattle,

Not to overly play into the stereotype of the TreeHugger moniker, but today is 4/20 so a quick review of all the great uses for industrial hemp--you

Industrial hemp farming could play a big role in providing economic stability in impoverished areas, creating jobs and businesses for veterans, and growing a sustainable and regenerative agriculture movement.

This revamp of an 1830s apartment mixes modern materials to create a modern space.

The move comes as a result of a petition from Greenpeace Southeast Asia, which asserts that GM crops can cause serious health issues.

Another look at a controversial housing project.

Scientists think there is a hidden, protected ocean inside of Pluto – and the implications are wild.

This short film, while focused on the island of Kauai, highlights the challenges and crises we will all have to face on our island planet.

Supported by the Amrita Bhoomi Agroecology Centre, young farmers are experimenting with natural farming methods, while saving money and lives in the process.

Waitrose wants to see how serious shoppers are about bringing their own containers.